Page 115 - Read Online

Page 14 of 15 Spencer et al. J Cancer Metastasis Treat 2022;8:2 https://dx.doi.org/10.20517/2394-4722.2021.174

doxorubicin in MG-63 osteosarcoma cells. Asian Pac J Cancer Prev 2011;12:239-45. PubMed
42. Zhang F, Chen A, Chen J, Yu T, Guo F. Influence of β-catenin small interfering RNA on human osteosarcoma cells. J Huazhong Univ
Sci Technolog Med Sci 2011;31:353-8. DOI PubMed
43. Ladhani O, Sánchez-Martinez C, Orgaz JL, Jimenez B, Volpert OV. Pigment epithelium-derived factor blocks tumor extravasation by
suppressing amoeboid morphology and mesenchymal proteolysis. Neoplasia 2011;13:633-42. DOI PubMed PMC
44. Tan ML, Choong PF, Dass CR. Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling,
adhesion and invasion. Biochem Biophys Res Commun 2010;398:613-8. DOI PubMed
45. Alcantara MB, Nemazannikova N, Elahy M, Dass CR. Pigment epithelium-derived factor upregulates collagen I and downregulates
matrix metalloproteinase 2 in osteosarcoma cells, and colocalises to collagen I and heat shock protein 47 in fetal and adult bone. J
Pharm Pharmacol 2014;66:1586-92. DOI PubMed
46. Xie Y, Sun W, Deng Z, Zhu X, Hu C, Cai L. MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2. Sci
Rep 2017;7:13388. DOI PubMed PMC
47. Xu E, Zhao J, Ma J, et al. miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by
targeting zinc and ring finger 3. Oncol Rep 2016;35:275-83. DOI PubMed
48. Elenjord R, Allen JB, Johansen HT, et al. Collagen I regulates matrix metalloproteinase-2 activation in osteosarcoma cells independent
of S100A4. FEBS J 2009;276:5275-86. DOI PubMed
49. Bjørnland K, Winberg JO, Odegaard OT, et al. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and
tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res
1999;59:4702. PubMed
50. Mathisen B, Lindstad RI, Hansen J, et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in
osteosarcoma cells. Clin Exp Metastasis 2003;20:701-11. DOI PubMed
51. Loennechen T, Mathisen B, Hansen J, et al. Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in
osteosarcoma cells in an S100A4-independent manner. Biochem Pharmacol 2003;66:2341-53. DOI PubMed
52. Bratland Å, Ragnhildstveit E, Bjørnland K, et al. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP
prostate carcinoma cells. Clin Exp Metastasis 2003;20:541-7. DOI PubMed
53. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev
Immunol 2004;4:617-29. DOI PubMed
54. Dass CR, Khachigian LM, Choong PF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008;7:1909-12.
DOI PubMed
55. Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Downregulation of c-jun results in apoptosis-mediated anti-
osteosarcoma activity in an orthotopic model. Cancer Biol Ther 2008;7:1033-6. DOI PubMed
56. Dass CR, Tan ML, Galloway SJ, Choong PF. Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumor cells
metastasizing to or from bone. Oligonucleotides 2010;20:79-91. DOI PubMed
57. Tan ML, Choong PF, Dass CR. Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and
MT1-MMP in tumours. Cancer Cell Int 2010;10:9. DOI PubMed PMC
58. Zhang G, Luo X, Sumithran E, et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of
matrix metalloproteinase-2 and -9 expression. Oncogene 2006;25:7260-6. DOI PubMed
59. Fromigué O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell
invasion. J Biol Chem 2008;283:30549-56. DOI PubMed PMC
60. Tsubaki M, Satou T, Itoh T, et al. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-
induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol 2012;259:402-10. DOI PubMed
61. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer
2011;117:1736-44. DOI PubMed PMC
62. Heikkilä P, Teronen O, Hirn MY, et al. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J Surg Res
2003;111:45-52. DOI PubMed
63. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma
cell lines. Pediatr Blood Cancer 2004;42:410-5. DOI PubMed
64. Xin ZF, Kim YK, Jung ST. Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 2009;28:105. DOI
PubMed PMC
65. Linder S. MT1-MMP: Endosomal delivery drives breast cancer metastasis. J Cell Biol 2015;211:215-7. DOI PubMed PMC
66. Sheehy S, Annabi B. A transcriptional regulatory role for the membrane type-1 matrix metalloproteinase in carcinogen-induced
inflammasome gene expression. Gene Regul Syst Bio 2017;11:1177625017713996. DOI PubMed PMC
67. ICONIC: Improving outcomes through collaboration in osteosarcoma. Available from: https://ClinicalTrials.gov/show/NCT04132895
[Last accessed on 6 Dec 2021].
68. Biology of osteosarcoma (BOOST) registry and biobank. Available from: https://clinicaltrials.gov/ct2/show/NCT03225872 [Last
accessed on 6 Dec 2021].
69. Beech T. Patient/parent osteosarcoma genome-wide registry (POWR) provides the sarcoma community with an underutilized resource
for genomic and medical history data. Available from: https://becauseofdaniel.org/the-science-of-powr/ [Last accessed on 6 Dec 2021].
70. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 2013;137:89-99. DOI
PubMed
71. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate.